Basking Biosciences

About Basking Biosciences

Basking Biosciences is dedicated to revolutionizing acute thrombosis treatment by developing a novel first-line therapy targeting von Willebrand Factor. Their mission is to provide safer, more effective treatments, starting with acute ischemic stroke, to expand the population receiving acute revascularization therapy.

Products & Services

BB-031:A first-in-class reversible RNA aptamer designed as a thrombolytic therapy for acute ischemic stroke, currently in Phase II clinical trials. It can be quickly neutralized by BB-025 in case of bleeding complications.

Specialties

Acute Thrombosis Treatment RNA Aptamer Technology Ischemic Stroke Therapy Reversible Thrombolytic Therapy Targeting von Willebrand Factor

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Venture Financing T: - FT: Venture Financing	A: 55000000 MR: - FA: 55 million FAN: 55000000	D: 2024-02-01 FD: 2024-02-01	8 investors

Venture Financing Latest

2024-02-01

$55.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Bruce Sullenger

Founder and Scientific Advisor

S

Shahid Nimjee

Founder and Chief Medical Officer

R

Richard Shea

Chief Executive Officer

R

Rob Hughes

Chief Financial Officer

L

Leo Pavliv

Head of CMC

M

Michael Hill

Clinical Program Advisor

View 20 more team members with Pro

Unlock Full Team Directory

Recent News